23 Nov 2023 • Patients with metabolic-associated steatotic liver disease (MASLD, formerly NAFLD) without cirrhosis who took daily low-dose aspirin in a double-blind randomized trial demonstated significant reductions in liver fat content over 6 months compared with similar patients who took a placebo, according to data presented at The Liver Meeting.

• Aspirin produced a 59.2% reduction in liver fat compared with placebo, and 40% of those who received aspirin achieved a relative reduction in HFF of at least 30% compared with 12.5% of those on placebo.
• Participants in the aspirin group also had a significantly greater reduction in hepatic fat measured by MRI-PDFF compared with placebo.
• Aspirin was also associated with significantly greater reductions in liver transaminase levels and liver stiffness by VCTE.

Overall, study findings suggest that aspirin represents a potential therapeutic option for MASLD, one which is economical, safe and well-tolerated.

Source: Medscape | Read full story